MOBI Mobia Medical, Inc. Insider Trading

Osage University GP III acquires 3.4M shares via conversions and open-market buys; 10% owner joins 5 other insiders buying within two weeks of IPO.

Osage University GP III, a 10% institutional shareholder, deployed substantial capital to acquire over 3.4 million shares on the day of this filing, combining stock conversions with open-market purchases at the company's current trading price. This institutional activity coincides with a broader pattern: five other insiders have also purchased shares within a two-week window around the IPO, suggesting broad appetite for Mobia Medical's stock among major stakeholders at or near its listing price. As a fund rather than an officer or director, Osage's activity reflects portfolio management decisions rather than insider operational knowledge, but the coincidence of multiple 10% holders and other insiders buying into a newly listed company is noteworthy. The stock has virtually no trading history beyond the IPO, making price context limited, and fundamental data is absent from the filing. The sheer volume of this institutional acquisition—coupled with the cluster of other insider buying—indicates significant capital flow into the company during its earliest public trading days.

Director Tansey Casey M acquires nearly 3.9M shares in open-market purchase, part of a five-insider buying wave within a 14-day window at newly listed company.

Director Tansey Casey M, who is also a 10% beneficial owner, made a substantial open-market purchase of nearly 3.9 million shares on the company's second day of trading. The transaction includes one open-market purchase at $15 per share (worth just under $1 million) plus three stock conversions, significantly expanding his ownership stake. This purchase arrives as part of a broader pattern: five insiders bought shares within a 14-day window, suggesting multiple company stakeholders saw value at the current price level. The stock is trading modestly above its listing price on a newly public company with only one prior day of trading history, making price-context analysis difficult. Tansey's track record as a buyer shows a positive 30-day return on his prior open-market purchase but a negative 90-day return, indicating mixed timing results on his previous acquisition.

Director and 10% owner Harrington acquires 3.4M shares via open-market purchases and conversions; three insiders buying within 14-day window.

William T Harrington, a director and 10% beneficial owner of Mobia Medical, executed a substantial acquisition of over 3.4 million shares on a single date through both open-market purchases and warrant conversions. This is Harrington's first open-market purchase activity in the available filing history, marking a notable shift into accumulation. The acquisition occurs alongside two other insiders purchasing shares within the same 14-day window, creating a pattern of multiple insiders deploying capital at the same time. The stock is trading above its 52-week low, recently listed, making this early-stage buying activity notable in terms of timing and scale relative to his existing ownership stake.

Director Lucchese buys 125,000 shares for $1.875M on day of IPO; 4 insiders buying in same window.

Lucchese Cynthia L, a director of Mobia Medical, purchased 125,000 shares at the IPO price on the company's first trading day as part of a broader wave of insider buying—four insiders bought open-market shares within a two-week window. This represents her second open-market purchase in the 36-month tracking window, following a prior buy that subsequently declined; her historical track record shows purchases that have not appreciated after acquisition. The timing is notable: she is buying at the IPO price itself rather than waiting for secondary trading, and the cluster of director-level purchases on the opening trading day is unusual. Without longer trading history or financial fundamentals available, the significance of this trade depends on how Mobia's stock performs after listing and whether this wave of director purchases reflects underlying confidence in the company's prospects or merely represents pre-planned IPO allocations.

Officer Leavitt makes first open-market purchase of 3,000 shares at $15, marking departure from stock-comp-only activity.

Leavitt Chase C., an officer at Mobia Medical, deployed personal capital to purchase 3,000 shares at $15 on the company's filing date. This is significant because it marks the first time this insider has bought shares on the open market—all prior Form 4 activity in the 36-month window consisted of stock-based compensation transactions. The transition from receiving equity as part of compensation to voluntarily purchasing shares with personal funds is a meaningful behavioral shift. Given the company is newly listed with minimal trading history, price context is limited, but the willingness to buy into a recently public company suggests this officer sees enough value to make an out-of-pocket commitment. Without longer-term pricing or performance data, the full significance of this purchase relative to the IPO price remains unclear.

Director Dana G Mead Jr. buys 7,000 shares of MOBI in first open-market purchase after prior stock-based compensation activity.

Director Dana G Mead Jr. deployed personal capital to acquire 7,000 shares on the open market, marking a shift from receiving stock through compensation arrangements to making an active open-market purchase decision. This is his first open-market buy in the 36-month window, distinguishing the trade from the nine prior stock-based compensation transactions on his record. The purchase occurred while the stock trades near its recent trading range, with the broader context that MOBI is a newly listed company with limited trading history. A director buying with personal capital—rather than exercising or disposing of granted shares—typically reflects a view that the current valuation warrants direct investment, though the transaction alone does not indicate financial health or near-term catalysts.